Cardiovascular Risk Factors in Renal Transplant Patients after Switch From Standard Tacrolimus to Prolonged-Release Tacrolimus

Sessa, A.; Esposito, A.; Iavicoli, G.; Lettieri, E.; Ragosta, G.; Rossano, R.; Capuano, M.

doi:10.1016/j.transproceed.2012.05.060

Cited by 9 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in HDL levels and decrease in triglycerides was observed with Advagraf®. An interesting finding was observed in a Caucasian study which demonstrated an improvement in lipid profile following conversion to oncedaily tacrolimus (13). Low HDL and hypertriglyceridaemia are among risk factors associated with increased cardiovascular risk.…”

Section: Discussionmentioning

confidence: 85%

Safety and Efficacy of Two Tacrolimus Formulations (Prograf® and Advagraf®) in Malaysian Renal Transplant Patients: A Comparative Study

Adnan

et al. 2019

JUMMEC

View full text Add to dashboard Cite

Aim: A once-daily formulation of tacrolimus, Advagraf®, is increasingly being used in place of twice-daily tacrolimus, Prograf®, as a standard immunosuppressive agent for transplant patients. In this study, the clinical safety and efficacy of Advagraf® were compared with Prograf®, among multi-ethnic Malaysian renal transplanted population. Method: This retrospective study identified renal transplant patients who were converted from Prograf ® to Advagraf ® at the University Malaya Medical Centre (UMMC) (n=69). Clinical notes and laboratory records, including tacrolimus daily dose and trough levels, were obtained for one-year, pre-and post-conversion. Causality assessment of suspected adverse events were based on the WHO-Uppsala Monitoring Center criteria. Renal biopsy records were re-evaluated based on the updated Banff 2007 classification for biopsy-confirmed acute rejection (BPAR). Results: Following conversion to Advagraf®, the mean tacrolimus trough level and daily dose decreased significantly (p<0.01) from 6.11±2.15 to 4.91±1.25 ng/mL and 4.08±2.19 to 3.48±1.79 mg/day, respectively. There was no significant difference in serum creatinine and estimated glomerular function. HDL was significantly increased (p=0.005) while triglycerides was significantly decreased following conversion to Advagraf® (p=0.003). The incidence of BPAR was 16% (4 cases in Prograf® and 7 cases in Advagraf®). No patients died or lost their grafts during the study period. There were 34 cases of adverse events which were classified as certain (5%), probable (36%), possible (23%) and unlikely (36%) with no significant difference between groups. Conclusion: Prograf® and Advagraf® tacrolimus formulations have comparable safety and efficacy profiles among Malaysian renal transplant patients. Advagraf® may have an advantage in terms of lipid profile.

show abstract

Section: Discussionmentioning

confidence: 85%

Safety and Efficacy of Two Tacrolimus Formulations (Prograf® and Advagraf®) in Malaysian Renal Transplant Patients: A Comparative Study

Adnan

et al. 2019

JUMMEC

View full text Add to dashboard Cite

show abstract

“…A retrospective analysis in de novo KTR converted to TAC MR4 from TAC within the immediate post-transplant period showed that TAC C 0 levels remained unchanged in 33%, and doses increased in 47%, and decreased in 20% [50]. The eGFR was reported to remain unchanged after conversion from TAC to TAC MR4 [19, 51], conversely other studies found an increased eGFR with TAC MR4 [44, 52, 53]. A per protocol analysis of the conversion from CSA to TAC MR4 in KTR showed no difference of graft function after 24 weeks [54].…”

Section: Discussionmentioning

confidence: 99%

A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes

et al. 2019

View full text Add to dashboard Cite

In this non-randomized extension study of a randomized controlled trial we converted 87 stable long-term kidney transplant recipients (KTR) from either ciclosporin (CSA, n = 28) or tacrolimus (TAC, n = 59) to TAC modified release (TAC MR4) to study the characteristics of TAC trough levels after conversion with the primary endpoint graft function after 12 months. TAC MR4 consumption was calculated by level-to-dose ([ng/mL]/[mg/d]) and concentration-to-dose ([mg/kg])/d) ratios. Influences of ABCB1 single nucleotide polymorphisms (2677G>T/A, 1236C>T, 3435C>T) on TAC metabolism were studied. Graft function of KTR converted from CSA to TAC MR4 significantly declined over 12 months, and remained unchanged after conversion from TAC to TAC MR4. Conversion from CSA to TAC MR4 resulted in supra therapeutic- and conversion from TAC to TAC MR4 in low trough levels. We could not find associations of ABCB1 genotypes and TAC MR4 trough levels. Adverse events and errors with TAC/TAC MR4 intake were common. In stable long-term KTR conversion from TAC to TAC MR4 is feasible. For conversion from CSA we suggest a rate of 1:40 for a rough estimation of TAC MR4 target doses. Trial registration PEP Study: Ethics committee N° 393/2004, EudraCT 2004-004209-98. PEP-X Study: Ethics committee amendment application N° 154/01/2008. ClinicalTrials.gov NCT03751332 .

show abstract

“…With tacrolimus commercially developed and distributed by local companies and with an adjusted ratio of medical insurance reimbursement, numerous patients prefer the oral administration of tacrolimus over cyclosporin A. Introduction of the sustained-release capsule can further increase compliance and improve patients' quality of life (Hatakeyama et al, 2012;Nakamura et al, 2012;Sessa et al, 2012). Among the 74 patients included in our study, 41 who were treated with the CsA + MMF + pred scheme decided to replace this treatment with the FK506 + MMF + pred scheme within 1 month to 5 years after renal transplantation.…”

Section: Discussionmentioning

confidence: 99%

Analysis of tacrolimus blood concentrations in renal transplant patients

Wang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study aimed to 1) analyze the results of tacrolimus blood concentration monitored in patients after renal transplantation, 2) observe and establish an optimal therapeutic window for patients, and 3) provide evidence for the clinical and rational use of drugs. Tacrolimus blood concentration was determined by enzyme-linked immunosorbent assay. A total of 1824 cases were obtained from the monitoring of 74 patients after renal transplantation. These cases were then retrospectively analyzed. Over time, the mean whole blood tacrolimus trough concentration after transplantation gradually decreased. This result suggests that the optimal therapeutic windows for patients with renal transplants are as follows: 5 to 20 µg/L at 1 month after surgery; 5 to 15 µg/L at 1-3 months after surgery; 4 to 12 µg/L at 3-6 months after surgery; 4 to 10 µg/L at 6-12 months after surgery; and 3 to 8 µg/L at >12 months after surgery. The absorption of tacrolimus is highly variable. Therefore, tacrolimus concentration in the blood and the recommended clinical therapeutic window should be routinely monitored to adjust the treatment regimen and reduce adverse reactions. In this way, treatment can be optimized.

show abstract

Cardiovascular Risk Factors in Renal Transplant Patients after Switch From Standard Tacrolimus to Prolonged-Release Tacrolimus

Cited by 9 publications

References 49 publications

Safety and Efficacy of Two Tacrolimus Formulations (Prograf® and Advagraf®) in Malaysian Renal Transplant Patients: A Comparative Study

Safety and Efficacy of Two Tacrolimus Formulations (Prograf® and Advagraf®) in Malaysian Renal Transplant Patients: A Comparative Study

A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes

Analysis of tacrolimus blood concentrations in renal transplant patients

Contact Info

Product

Resources

About